EP Patent

EP2859886A1 — A pharmaceutical spray composition

Assigned to Leo Pharma AS · Expires 2015-04-15 · 11y expired

What this patent protects

The present invention relates to a topical spray composition comprising a calcipotriol or calcipotriol monohydrate and a therapeutically effective amount of betamethasone dipropionate being dissolved in a pharmaceutically acceptable propellant mixture comprising dimethyl ether a…

USPTO Abstract

The present invention relates to a topical spray composition comprising a calcipotriol or calcipotriol monohydrate and a therapeutically effective amount of betamethasone dipropionate being dissolved in a pharmaceutically acceptable propellant mixture comprising dimethyl ether as a first propellant and a second propellant selected from the group consisting of C3-5alkanes, hydrofluoroalkanes, hydrochloroalkanes, fluoroalkanes and chlorofluoroalkanes, the composition further comprising a pharmaceutically acceptable lipid carrier solubilized or suspended in said propellant mixture.

Drugs covered by this patent

Patent Metadata

Patent number
EP2859886A1
Jurisdiction
EP
Classification
—
Expires
2015-04-15
Drug substance claim
No
Drug product claim
No
Assignee
Leo Pharma AS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.